FRESH TRACKS THERAPEUTICS IN (FRTX)

Company Profile

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.

Company Info

FRESH TRACKS THERAPEUTICS IN

5777 Central Ave Ste 102

Boulder COLORADO

P: 17205054755

Employees: 13

Website: https://www.frtx.com/